|
Name |
Cyclo(L-Tyr-L-Pro-L-Phe-trans-4-hydroxy-L-Pro)
|
Molecular Formula | C28H32N4O6 | |
IUPAC Name* |
(3S,6S,8R,12S,15S)-3-benzyl-8-hydroxy-12-[(4-hydroxyphenyl)methyl]-1,4,10,13-tetrazatricyclo[13.3.0.06,10]octadecane-2,5,11,14-tetrone
|
|
SMILES |
C1C[C@H]2C(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@H](C(=O)N2C1)CC4=CC=CC=C4)O)CC5=CC=C(C=C5)O
|
|
InChI |
InChI=1S/C28H32N4O6/c33-19-10-8-18(9-11-19)14-22-28(38)32-16-20(34)15-24(32)26(36)30-21(13-17-5-2-1-3-6-17)27(37)31-12-4-7-23(31)25(35)29-22/h1-3,5-6,8-11,20-24,33-34H,4,7,12-16H2,(H,29,35)(H,30,36)/t20-,21+,22+,23+,24+/m1/s1
|
|
InChIKey |
ZGIGRYSYJMUJMP-DFWAIWNTSA-N
|
|
Synonyms |
Cyclo(L-Tyr-L-Pro-L-Phe-trans-4-hydroxy-L-Pro)
|
|
CAS | NA | |
PubChem CID | 139583586 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 520.6 | ALogp: | 1.4 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 139.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.464 |
Caco-2 Permeability: | -6.269 | MDCK Permeability: | 0.00000521 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.095 |
Human Intestinal Absorption (HIA): | 0.845 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.033 | Plasma Protein Binding (PPB): | 63.98% |
Volume Distribution (VD): | 0.299 | Fu: | 40.18% |
CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.042 |
CYP2C19-inhibitor: | 0.181 | CYP2C19-substrate: | 0.075 |
CYP2C9-inhibitor: | 0.534 | CYP2C9-substrate: | 0.872 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.238 |
CYP3A4-inhibitor: | 0.819 | CYP3A4-substrate: | 0.202 |
Clearance (CL): | 3.885 | Half-life (T1/2): | 0.735 |
hERG Blockers: | 0.121 | Human Hepatotoxicity (H-HT): | 0.98 |
Drug-inuced Liver Injury (DILI): | 0.529 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.933 | Maximum Recommended Daily Dose: | 0.911 |
Skin Sensitization: | 0.121 | Carcinogencity: | 0.054 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.025 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004971 | 0.558 | D0J7XL | 0.358 | ||||
ENC002149 | 0.554 | D0E2OU | 0.355 | ||||
ENC003593 | 0.504 | D09PZZ | 0.354 | ||||
ENC005092 | 0.500 | D0V3ZA | 0.351 | ||||
ENC002030 | 0.500 | D0U7SH | 0.349 | ||||
ENC005408 | 0.500 | D0SP3D | 0.346 | ||||
ENC000867 | 0.500 | D0N4OW | 0.346 | ||||
ENC005847 | 0.500 | D01TSI | 0.343 | ||||
ENC005206 | 0.500 | D0I0DL | 0.341 | ||||
ENC005484 | 0.481 | D09NNH | 0.341 |